Perrigo wins US FDA tentative approval for generic Finacea Foam, 15%
19 March 2019 -

Health and wellness company Perrigo Company plc (NYSE; TASE: PRGO) reported on Monday that it has received US Food and Drug Administration tentative approval for the generic version of Finacea Foam(azelaic acid) 15%.

The company added that it had announced a patent litigation suit with Bayer AG for the Finacea Foam (azelaic acid) 15%.

In conjunction with the patent litigation suit, LEO Pharma A/S acquired Finacea Foam (azelaic acid) 15% from Bayer AG and then substituted for Bayer AG as the lead plaintiff in the patent litigation suit concerning the product.

For the 12 months ending January 2019, the annual market sales were approximately USD62m as measured by IQVIA.